The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Norry Elliot since 2020.
This trader's CIK number is 1798117.
At the time of last reporting, Norry Elliot was the Chief Medical Officer of Adaptimmune Therapeutics Plc. (stock ticker symbol ADAP).
Also see all insider trading activities at Adaptimmune Therapeutics Plc.
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2025 | ADAP | 0 | $0 | 27,779 | $16,166 | 0 | $0 |
| 2024 | ADAP | 0 | $0 | 32,371 | $24,120 | 0 | $0 |
| 2023 | ADAP | 0 | $0 | 14,327 | $24,914 | 0 | $0 |
| 2022 | ADAP | 0 | $0 | 7,594 | $26,655 | 0 | $0 |
| 2021 | ADAP | 0 | $0 | 3,797 | $21,644 | 0 | $0 |
| 2020 | ADAP | 0 | $0 | 911 | $4,677 | 0 | $0 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-01-17 | ADAP | Sale | 5,584 | .58 | 3,244 |
| 2025-01-13 | ADAP | Sale | 12,392 | .59 | 7,286 |
| 2025-01-15 | ADAP | Sale | 9,803 | .57 | 5,636 |
| 2024-01-16 | ADAP | Sale | 2,287 | .79 | 1,806 |
| 2024-01-17 | ADAP | Sale | 18,276 | .67 | 12,299 |
| 2024-01-11 | ADAP | Sale | 4,009 | .84 | 3,355 |
| 2024-01-12 | ADAP | Sale | 7,799 | .85 | 6,660 |
| 2023-01-17 | ADAP | Sale | 2,159 | 1.86 | 4,011 |
| 2023-01-11 | ADAP | Sale | 3,843 | 1.75 | 6,713 |
| 2023-01-12 | ADAP | Sale | 7,449 | 1.71 | 12,707 |
| 2023-01-04 | ADAP | Sale | 876 | 1.69 | 1,483 |
| 2022-01-18 | ADAP | Sale | 2,121 | 3.19 | 6,770 |
| 2022-01-11 | ADAP | Sale | 3,770 | 3.56 | 13,409 |
| 2022-01-12 | ADAP | Sale | 854 | 3.54 | 3,026 |
| 2022-01-04 | ADAP | Sale | 849 | 4.06 | 3,450 |
| 2021-01-19 | ADAP | Sale | 2,111 | 5.67 | 11,969 |
| 2021-01-12 | ADAP | Sale | 841 | 6.15 | 5,173 |
| 2021-01-04 | ADAP | Sale | 845 | 5.33 | 4,502 |
| 2020-01-14 | ADAP | Sale | 911 | 5.13 | 4,677 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Norry Elliot (Chief Medical Officer of Adaptimmune Therapeutics Plc at the time of this reporting) see the Securities and Exchange Commission (SEC) website.